64 results about "Attention deficits" patented technology

The invention discloses an attention deficit hyperactivity disorder recognition system and recognition method, and belongs to the technical field of attention deficit hyperactivity disorder. The data processing module is used for carrying out preprocessing and feature extraction on the acquired electroencephalogram data; a multi-source feature fusion mechanism is firstly used for the extracted original feature data, and then a data enhancement strategy is applied; a multi-source fusion feedback regulation network model is constructed, wherein the model is of a CNN-GRU parallel modeling structure; the training module is used for inputting the enhanced data into a model for training, key hyper-parameters are dynamically adjusted by a performance feedback adjusting mechanism in the training process, and the performance feedback adjusting mechanism is used for dynamically adjusting key training parameters according to the performance of the verification set; and the classification module is used for classifying to-be-detected samples through the trained multi-source fusion feedback regulation network model and outputting a final recognition result. The ADHD electroencephalogram recognition method effectively improves the accuracy, robustness and generalization performance of ADHD electroencephalogram recognition.

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

The disclosure relates to, in part, a method of diagnosing whether a patient is afflicted with attention-deficit / hyperactivity disorder (ADHD) and / or selecting ADHD treatment for a patient afflicted with ADHD and / or monitoring response of ADHD symptoms in patient to an ADHD treatment.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

1. The name of the design product: eye movement cognitive and attention assessment training instrument. 2. The use of the design product: for attention deficit groups such as hyperactivity and autism. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The present invention relates to attention training systems and methods, particularly for treating individuals with Attention-Deficit / Hyperactivity Disorder (ADHD). Specifically, the present invention is related to employing biofeedback and virtual reality technologies to enhance gaze control and attention measures. The claimed invention represents a system and method for attention training that improve the relevant technological field by providing and utilizing a highly informative real-time biofeedback reliably representing the user's ability to sustain attention.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for preventing or treating chemobrain, e.g., inhibiting or mitigating one or more symptoms of chemobrain, e.g., feeling of mental fogginess, deficit in attention, disorganized behavior or thinking, confusion, impaired concentration, difficulty finding the right word, difficulty learning new skills, difficulty multitasking, memory impairment (e.g., short-term memory problems, long-term memory problems, impaired verbal memory, impaired visual memory), and / or fatigue.

The present invention relates to the treatment of an executive function disorder, such as attention deficit hyperactivity disorder (ADHD) and / or autism with both lacosamide and oxcarbazepine.

This application relates to a method, apparatus, and device for screening the risk of reading and attention deficit disorder in children. The method includes acquiring multi-channel raw brain blood oxygenation signals under task-induced conditions using a specific layout fNIRS array integrated into a wearable headband, based on a rapid naming cognitive paradigm. Based on the raw brain blood oxygenation signals, a fusion feature vector representing the reading and attention networks is generated by calculating temporal waveform features and frontotemporal functional connectivity strength. The multi-dimensional fusion feature vector is then processed and analyzed using a Transformer classification model to generate classification results indicating the risk level of reading disorders and comorbid ADHD. This application achieves portable and rapid brain function signal acquisition by integrating a targeted fNIRS array with a standardized cognitive paradigm. By fusing temporal dynamics and brain network connectivity features, a multi-dimensional neural representation is constructed. Finally, a lightweight Transformer model is used to output the risk level of reading disorders and comorbid ADHD end-to-end, achieving high-precision automated assisted screening.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present disclosure discloses an attention system and method for users with attention- deficit / hyperactivity disorder (ADHD), the system (100) comprises a server (102) configured to manage tasks and enable communication between a mobile application (104) and remote devices (106) over a wireless communication medium (108) The system includes a patient identification and registration module (115) for user authentication, a patient input module (116) to collect preferences, and a task presentation module (101) for delivering attention tasks in multiple formats. An automated scoring module (105) tracks performance metrics and provides real-time feedback, while an adaptive module (110) adjusts task complexity based on user performance. The system offers personalized rewards through a motivation module (103), stores user data securely with a data storage module (114), and analyses performance over time with a data analysis module (111). The system is configured for both children and adults, ensuring wide accessibility and engagement.

The present invention relates to therapeutic compositions and methods for the treatment of attention deficit disorder (ADD), or attention deficit hyperactivity disorder (ADHD). The present invention more particularly relates to a modified-release pharmaceutical formulation designed to improve the delivery and efficacy of central nervous system (CNS) stimulants. The composition consists of a drug-containing core with a CNS stimulant and pharmaceutically acceptable excipients. This core is coated with a sustained-release (SR) layer comprising one or more polymers selected from water-insoluble and water-insoluble pH-dependent polymers, and one or more pharmaceutically acceptable excipients which regulates the gradual release of the drug. Surrounding the SR layer is a delayed-release (DR) outer layer that controls the onset of drug release. This approach aims to enhance symptom control, reduce dosing frequency, and improve patient compliance in the treatment of ADD and ADHD.

The invention relates to a pellet as well as a preparation method and application thereof. The pellet has a treatment effect on attention deficit and attention disorder of children. The invention also provides a tablet containing the pellet, the tablet comprises active pharmaceutical ingredients and pharmaceutically acceptable auxiliary materials, and the active pharmaceutical ingredients exist in the core pellet. The pellet and the tablet containing the pellet have a good release characteristic.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention discloses a children attention deficit early intelligent screening system based on multi-modal behavior feature fusion. The system comprises a data acquisition module, a data processing module and a data classification judgment module. The data acquisition module is used for acquiring handwriting data, action feature data and facial expression feature data of a child; the data processing module is used for performing space-time alignment and feature level fusion on the acquired handwriting data, action feature data and facial expression feature data to obtain processed data; and the data classification and judgment module is used for carrying out classification and judgment on the processed data to obtain a screening result and finish early intelligent screening of the attention deficits of children. According to the invention, the Microsoft Surface touch device and the external camera are used for collecting the bottom data in the drawing process of children in real time, and computer vision and a machine learning algorithm are combined, so that the attention defect screening function is realized.

Described herein is the use of nasally-administered oxytocin-based therapeutics to improve cognitive control in individuals with attention-deficit / hyperactivity disorder (ADHD).

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine composition for treating tourette syndrome combined attention deficit in children, a preparation, a preparation method and application. The traditional Chinese medicine composition is composed of radix bupleuri, fossil fragments, oysters, radix scutellariae, fresh ginger, ginseng, cassia twigs, poria cocos, pinellia ternate, Chinese dates, rhizoma acori graminei, uncaria rhynchophylla, fructus forsythiae, licorice roots and other medicinal materials, and has the effects of calming liver wind, reducing phlegm, inducing resuscitation, invigorating spleen, replenishing qi and harmonizing ying and wei. The traditional Chinese medicine composition is definite in curative effect, small in side effect and high in safety, and the effect is better than that of chemical medicines. The traditional Chinese medicine composition has a remarkable clinical curative effect on children tic disorder combined with attention deficit, especially liver wind internal movement phlegm entraining syndromes, and has a wide market popularization and application prospect.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

The system comprises a prediction module (1) equipped with artificial intelligence to predict neurological disorders in an individual patient and identify a level of neurological disorders; a central processing unit (2) to detect triggering events and circumstances due to which the neurological disorders trigger in an individual patient upon receiving real-time behavior information data generated by a playing ball (3) of an individual patient and distinguish between a normal behavior and a neurological disorders behavior; an alert module (4) to alert the individual patient upon determining neurological disorders behavior; and an entertainment platform (5) to entertain and engage the individual patient with a specific set of activities assigned according to detected triggering events and circumstances upon determining the neurological disorders behavior, wherein a specific set of activities includes listening to music, playing games, and talking to an AI chatbot.

The invention relates to a multifunctional medicine release composition as well as a preparation method and application thereof. The multifunctional medicine release composition has a treatment effect on attention deficit and attention disorder of children. The invention also provides a dispersible sustained-release multi-unit pellet system which comprises an active pharmaceutical ingredient and pharmaceutically acceptable auxiliary materials, and the active pharmaceutical ingredient exists in the core pellet. The invention also relates to a method for preparing the sustained-release multi-unit pellet system by adopting a multi-seal coating technology. The dispersible slow-release multi-unit pellet system disclosed by the invention has a good release characteristic.

This invention discloses a system and method for identifying Attention Deficit Hyperactivity Disorder (ADHD), belonging to the technical field of ADHD. The system includes: a data processing module for preprocessing and feature extraction of acquired EEG data; a multi-source feature fusion mechanism followed by data augmentation strategies for the extracted raw feature data; a multi-source fusion feedback regulation network model, employing a CNN-GRU parallel modeling structure; a training module for training the model using augmented data, dynamically adjusting key hyperparameters based on performance feedback on the validation set; and a classification module for classifying test samples using the trained multi-source fusion feedback regulation network model and outputting the final identification result. This invention effectively improves the accuracy, robustness, and generalization performance of ADHD EEG identification.

The invention provides an attention deficit hyperactivity disorder (ADHD) evaluation system and method based on deep learning. The system is composed of a data acquisition module, a deep learning module, an evaluation module, a result output module, a feedback adjustment module and a storage module. Multi-modal data such as high-resolution videos, high-quality audios and physiological signals are collected and processed through a multi-stream fusion convolutional neural network. According to the system, CNN, LSTM and an attention mechanism are creatively fused, and effective analysis and adaptive weight adjustment of multi-modal data are realized. And the evaluation module performs multi-dimensional evaluation by adopting a hierarchical strategy and a dynamic time window technology, and the result is presented in a visual mode. The system has continuous learning ability, performance is continuously optimized through a feedback mechanism, and data security is ensured by adopting distributed storage. The method improves the objectivity, accuracy and efficiency of ADHD evaluation, and is suitable for medical institutions, families and school environments.

To provide 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for treatment of depression and the like.SOLUTION: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of, e.g., depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are, e.g., 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present specification discloses the synthesis and characterization of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention.SELECTED DRAWING: None